Navigation Links
Combination therapy to treat breast cancer

The combination of two targeted drug therapies results in dramatic reduction in breast cancer cell growth in vitro, indicating a potentially powerful new approach to treating the condition.// The two drug agents – trastuzumab and ZD1839 were found to work synergistically to inhibit the action of two different growth factors receptors, HER2 and epidermal growth factor receptor (EGFR).

Previous research has shown that these growth factor receptors are involved in 20 and 70 per cent of breast cancers, respectively, and it has been suggested that they interact with one another to ensure cell proliferation and survival. Trastuzumab and ZD1839 have been specifically developed to target these receptors.

The agents were tested singly and then in combination. Individually, the drugs inhibited cell growth by between 30 and 55 per cent. Working together, trastuzumab and ZD1839 reduced cell proliferation by 70 per cent.

The findings suggest that simultaneous inhibition of the action of both growth factor receptors exerts a greater anti-tumour effect. The approach could be expanded to treat other types of cancer. Eventually, these combinations of drugs may be used with conventional cell-killing drugs. Alternatively, conventional chemotherapy may be used for short courses at times when the disease is more aggressive and targeted therapy used at other times.
'"/>




Page: 1

Related medicine news :

1. Consensus on "Combination Therapy" for Breast Cancer
2. Drug Combinations May Boost Stroke Risk
3. Combination regime may work against prostate cancer
4. Smoking and Breast Cancer - A Deadly Combination
5. New Drug Combination Found To Improve Memory in Alzheimer’s Patient
6. A Combination Of Drugs Effective In The Treatment Of Hormone-Refractory Prostate Cancer
7. Combination Therapy Effective In Improving Lung Cancer Survival
8. Combination Therapy Found To Improves Stroke Recovery
9. Combination Therapy Found To Be More Effective In Treating Brain Cancer
10. Combination of Clopidogrel-aspirin is better for preventing stroke than only aspirin
11. New Combination Therapy Option for HIV Patients
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned ... developed to enhance the health of felines. The formula is all-natural and is made ... in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary ... Dallas that it will receive two significant new grants to support its work ... marked its 25th anniversary by recognizing patients, medical professionals and scientists for their ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  American Respiratory Labs (ARL), a ... now able to perform sophisticated lung assessments in patients, homes, thanks ... Inc. Patients are no longer limited to having ... PRO ® , ARL patients like Jeanne R. of ... the comfort of her own home. ...
(Date:6/24/2016)... According to a new market ... Needles, Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, ... of Purchase (Retail, Non-Retail) - Trends & Global Forecasts ... market for the forecast period of 2016 to 2021. ... by 2021 from USD 1.65 Billion in 2016, growing ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
Breaking Medicine Technology: